<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45029">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01652326</url>
  </required_header>
  <id_info>
    <org_study_id>UPittsburgh 0031860</org_study_id>
    <nct_id>NCT01652326</nct_id>
  </id_info>
  <brief_title>Clinical Quality Improvement of Benzodiazepine-Resistant Alcohol Withdrawal Syndrome</brief_title>
  <official_title>Clinical Quality Improvement of Benzodiazepine-Resistant Alcohol Withdrawal Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospira, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overarching goal of this project is to improve the clinical quality of patients with
      Benzodiazepine-resistant alcohol withdrawal syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">July 2013</completion_date>
  <primary_completion_date type="Anticipated">January 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>Identify those risk factors predictive of benzodiazepine-resistant alcohol withdrawal syndrome</measure>
    <time_frame>up to 38 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drug utilization of phenobarbital, propofol, dexmedetomidine, and ketamine in benzodiazepine-resistant alcohol withdrawal syndrome</measure>
    <time_frame>Up to 38 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Will compare the frequency, duration and dosages of the above agents when used for benzodiazepine-resistant alcohol withdrawal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness of phenobarbital, propofol, dexmedetomidine, and ketamine in benzodiazepine-resistant alcohol withdrawal</measure>
    <time_frame>Up to 38 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Comparative markers will include:
Presence or absence of the following: delirium tremens, hallucinosis, seizures, or arrhythmias
Indication and duration of mechanical intubation
Nosocomial infection rates
ICU length of stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability of phenobarbital, propofol, dexmedetomidine, and ketamine in benzodiazepine-resistant alcohol withdrawal</measure>
    <time_frame>Up to 38 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Comparative markers will include:
Rikers Sedation Scale Assessments
Hypotension
Hypertriglyceridemia/Pancreatitis
Drug induced hallucinosis or seizures</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Benzodiazepine-resistant Alcohol Withdrawal Syndrome</condition>
  <arm_group>
    <arm_group_label>Benzodiazepine-resistant</arm_group_label>
    <description>those patients with either 1) a requirement of either 200 mg of diazepam (or diazepam equivalents) in 4 hrs; 2) &gt;40mg of diazepam (or diazepam equivalents) in 1 hr; or 3) an individual dose of 40 mg or greater of intravenous diazepam for control of agitation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diazepam</intervention_name>
    <arm_group_label>Benzodiazepine-resistant</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        hospitalized inpatients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        either

          1. a requirement of either 200 mg of diazepam (or diazepam equivalents) in 4 hrs;

          2. &gt; 40mg of diazepam (or diazepam equivalents) in 1 hr; or

          3. an individual dose of 40 mg or greater of intravenous diazepam for control of
             agitation

        Exclusion Criteria:

          -  if &lt; 18 years of age or had evidence of use of other illicit substances as determined
             by urine toxicology screen
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <lastchanged_date>July 25, 2012</lastchanged_date>
  <firstreceived_date>July 20, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Substance Withdrawal Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diazepam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
